gemfibrozil has been researched along with Apoplexy in 10 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In men with coronary heart disease, low HDL cholesterol, and low LDL cholesterol, gemfibrozil reduces stroke incidence." | 9.09 | Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). ( Babikian, V; Bloomfield Rubins, H; Brass, LM; Collins, D; Davenport, J; Papademetriou, V; Robins, SJ; Rutan, G; Wagner, S; Wexler, L, 2001) |
| "In men with coronary heart disease, low HDL cholesterol, and low LDL cholesterol, gemfibrozil reduces stroke incidence." | 5.09 | Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). ( Babikian, V; Bloomfield Rubins, H; Brass, LM; Collins, D; Davenport, J; Papademetriou, V; Robins, SJ; Rutan, G; Wagner, S; Wexler, L, 2001) |
| " Efficacy of gemfibrozil was demonstrated in secondary stroke prevention in patients with coronary heart disease and elevated triglyceride levels." | 4.89 | Hypertriglyceridemia as a possible independent risk factor for stroke. ( Basić-Kes, V; Demarin, V; Lisak, M; Trkanjec, Z, 2013) |
| "Since dyslipidemia is common in diabetes and is associated with increased cardiovascular risk, we tested the hypothesis that Thr-54 is associated with increased cardiovascular risk in patients with diabetes." | 2.73 | Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the Veterans Affairs HDL intervention trial (VA-HIT). ( Bloomfield, H; Brousseau, ME; Collins, D; Georgopoulos, A; O'Connor, JJ; Ordovas, JM; Robins, SJ; Schaefer, EJ, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lisak, M | 1 |
| Demarin, V | 1 |
| Trkanjec, Z | 1 |
| Basić-Kes, V | 1 |
| Wang, D | 1 |
| Liu, B | 1 |
| Tao, W | 1 |
| Hao, Z | 1 |
| Liu, M | 1 |
| Jakob, T | 1 |
| Nordmann, AJ | 1 |
| Schandelmaier, S | 1 |
| Ferreira-González, I | 1 |
| Briel, M | 1 |
| Corvol, JC | 1 |
| Bouzamondo, A | 1 |
| Sirol, M | 1 |
| Hulot, JS | 1 |
| Sanchez, P | 1 |
| Lechat, P | 1 |
| Georgopoulos, A | 1 |
| Bloomfield, H | 1 |
| Collins, D | 3 |
| Brousseau, ME | 1 |
| Ordovas, JM | 1 |
| O'Connor, JJ | 1 |
| Robins, SJ | 3 |
| Schaefer, EJ | 1 |
| Nelson, JJ | 1 |
| Bloomfield, HE | 1 |
| Asztalos, BF | 1 |
| Plutzky, J | 1 |
| Ridker, PM | 1 |
| Athyros, VG | 1 |
| Papageorgiou, AA | 1 |
| Kontopoulos, AG | 1 |
| Bloomfield Rubins, H | 1 |
| Davenport, J | 1 |
| Babikian, V | 1 |
| Brass, LM | 1 |
| Wexler, L | 1 |
| Wagner, S | 1 |
| Papademetriou, V | 1 |
| Rutan, G | 1 |
| Rizos, E | 1 |
| Mikhailidis, DP | 1 |
5 reviews available for gemfibrozil and Apoplexy
| Article | Year |
|---|---|
Hypertriglyceridemia as a possible independent risk factor for stroke.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Gemfibrozil; Humans; Hypertriglyceridemia; Hyp | 2013 |
Fibrates for secondary prevention of cardiovascular disease and stroke.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Caus | 2015 |
Fibrates for primary prevention of cardiovascular disease events.
Topics: Atorvastatin; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Fenofibrate; Gemfibrozil; Humans | 2016 |
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; H | 2003 |
Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention?
Topics: Adult; Bezafibrate; Biomarkers; Cholesterol; Coronary Disease; Female; Follow-Up Studies; Gemfibrozi | 2001 |
3 trials available for gemfibrozil and Apoplexy
| Article | Year |
|---|---|
Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the Veterans Affairs HDL intervention trial (VA-HIT).
Topics: Aged; Codon; Diabetes Mellitus; Dyslipidemias; Fatty Acid-Binding Proteins; Gemfibrozil; Genetic Pre | 2007 |
Statin-fibrate combinations in patients with combined hyperlipedemia.
Topics: Clofibric Acid; Coronary Disease; Drug Therapy, Combination; Fibric Acids; Follow-Up Studies; Gemfib | 2001 |
Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT).
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Follow-Up Studies; Gemfibrozil; Humans; | 2001 |
2 other studies available for gemfibrozil and Apoplexy
| Article | Year |
|---|---|
Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Apolipoproteins B; Cardiovascular Diseases; Ch | 2008 |
Statins for stroke: the second story?
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; | 2001 |